The Parathyroid and Disorders of Calcium and Bone Metabolism

Brook's Clinical Pediatric Endocrinology: Sixth Edition

Volumn , Issue , 2010, Pages 374-427

  Allgrove, Jeremy ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Autosomal dominant hypocalcemia (ADH); Calcium and phosphate maintaining normal neuromuscular and cellular functions; Cholecalciferol as a result of action of ultraviolet (UV) light; Ergocalciferol and synthesis by plants; Fibroblast growth factor receptors (FGFRs); Parathyroid (PT) glands; Parathyroid and calcium and bone metabolism disorders; Parathyroid hormone single chain 84 amino acid polypeptide hormone encoded by gene on chromosome 11; Renal tubular transport by paracellular and transcellular mechanisms; Vitamin d in two forms, cholecalciferol, ergocalciferol

Indexed keywords

EID: 84868310308     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316728.ch16     Document Type: Chapter

References (127)

1. Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev 2005;85:373-422.
2. Heaney RP. Nutrition and risk of osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, 2001.
3. Friedman PA, Gesek FA. Cellular calcium transport in renal epithelia: measurement, mechanisms and regulation. Physiol Rev 1995;75:429-471.
4. Kruse K, Kracht U, Kruse U. Reference values for urinary calcium excretion and screening for hypercalciuria in children and adolescents. Eur J Pediatr 1984;143:25-31.
5. Groenestege WM, Thebault S, van der WJ, van den BD, Janssen R, Tejpar S, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007;117:2260-2267.
6. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975;2:309-310.
7. Kruse K, Kracht U, Gopfert G. Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 1982;57:217-223.
8. Smith M, Weiss MJ, Griffin CA, Murray JC, Buetow KH, Emanuel BS, et al. Regional assignment of the gene for human liver/bone/ kidney alkaline phosphatase to chromosome 1p36.1-p34. Genomics 1988;2:139-143.
9. Round JM, Butcher S, Steele R. Changes in plasma inorganic phosphorus and alkaline phosphatase activity during the adolescent growth spurt. Ann Hum Biol 1979;6:129.
10. Kronenberg HM, Bringhurst FR, Segre GV, Potts JT. Parathyroid hormone biosynthesis and metabolism. In: Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids: Basic and Clinical Concepts. San Diego: Academic Press, 2001, pp. 17-30.
11. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001;81:239-297.
12. Conlin PR, Fajtova VT, Mortensen RM, LeBoffMS, Brown EM. Hysteresis in the relationship between serum ionized calcium and intact parathyroid hormone during recovery from induced hyperand hypocalcemia in normal humans. J Clin Endocrinol Metab 1989;69:593-599.
13. Parfitt AM. Parathyroid growth: normal and abnormal. In: Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids: Basic and Clinical Concepts. San Diego: Academic Press, 2001, pp. 293-330.
14. Nissensen RA. Receptors for parathyroid hormone and parathyroid hormone-related protein: signaling and regulation. In: Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids: Basic and Clinical Concepts. San Diego: Academic Press, 2001, pp. 93-104.
15. Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med 1999;340:1012-1020.
16. Okuda K, Usui E, Ohyama Y. Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. J Lipid Res 1995;36:1641-1652.
17. St Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 1997;12:1552-1559.
18. Awumey EM, Mitra DA, Hollis BW, Kumar R, Bell NH. Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. J Clin Endocrinol Metab 1998;83:169-173.
19. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-349.
20. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007;117:2684-2691.
21. Francis F, Strom TM, Hennig S, Boddrich A, Lorenz B, Brandau O, et al. Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 1997;7:573-585.
22. Martin TJ, Moseley JM, Williams ED. Parathyroid hormone-related protein: hormone and cytokine. J Endocrinol 1997;154 (Suppl): S23-S37.
23. Allgrove J, Adami S, Manning RM, O'Riordan JL. Cytochemical bioassay of parathyroid hormone in maternal and cord blood. Arch Dis Child 1985;60:110-115.
24. Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 2006;7:33-39.
25. Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev Endocr Metab Disord 2006;7:41-49.
26. Stein GS, Lian JB, van Wijnen AJ, Stein JL, Montecino M, Javed A, et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004;23:4315-4329.
27. Byers PH, Krakow D, Nunes ME, Pepin M. Genetic evaluation of suspected osteogenesis imperfecta (OI). Genet Med 2006;8:383-388.
28. Fewtrell MS. Bone densitometry in children assessed by dual X-ray absorptiometry: uses and pitfalls. Arch Dis Child 2003;88:795-798.
29. Rauch F. Watching bone cells at work: what we can see from bone biopsies. Pediatr Nephrol 2006;21:457-462.
30. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000;11:281-294.
31. Sharp M. Bone disease of prematurity. Early Hum Dev 2007;83:653-658.
32. Shiohara M, Shiozawa R, Kurata K, Matsuura H, Arai F, Yasuda T, et al. Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor. Endocr J 2006;53:797-802.
33. Sayer JA, Pearce SH. Extracellular calcium-sensing receptor dysfunction is associated with two new phenotypes. Clin Endocrinol (Oxf) 2003;59:419-421.
34. Bassett JH, Thakker RV. Molecular genetics of disorders of calcium homeostasis. Baillieres Clin Endocrinol Metab 1995;9:581-608.
35. Ding C, Buckingham B, Levine MA. Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. J Clin Invest 2001;108:1215-1220.
36. Baumber L, Tufarelli C, Patel S, King P, Johnson CA, Maher ER, et al. Identification of a novel mutation disrupting the DNA binding activity of GCM2 in autosomal recessive familial isolated hypoparathyroidism. J Med Genet 2005;42:443-448.
37. Maret A, Ding C, Kornfield SL, Levine MA. Analysis of the GCM2 gene in isolated hypoparathyroidism: a molecular and biochemical study. J Clin Endocrinol Metab 2008;93:1426-1432.
38. Gong W, Emanuel BS, Collins J, Kim DH, Wang Z, Chen F, et al. A transcription map of the DiGeorge and velo-cardio-facial syndrome minimal critical region on 22q11. Hum Mol Genet 1996;5:789-800.
39. Scambler PJ, Carey AH, Wyse RK, Roach S, Dumanski JP, Nordenskjold M, et al. Microdeletions within 22q11 associated with sporadic and familial DiGeorge syndrome. Genomics 1991;10:201-206.
40. Augusseau S, Jouk S, Jalbert P, Prieur M. DiGeorge syndrome and 22q11 rearrangements. Hum Genet 1986;74:206.
41. Yamagishi H, Garg V, Matsuoka R, Thomas T, Srivastava D. A molecular pathway revealing a genetic basis for human cardiac and craniofacial defects. Science 1999;283:1158-1161.
42. Ammann AJ, Wara DW, Cowan MJ, Barrett DJ, Stiehm ER. The DiGeorge syndrome and the fetal alcohol syndrome. Am J Dis Child 1982;136:906-908.
43. Scire G, Dallapiccola B, Iannetti P, Bonaiuto F, Galasso C, Mingarelli R, et al. Hypoparathyroidism as the major manifestation in two patients with 22q11 deletions. Am J Med Genet 1994;52:478-482.
44. Ali A, Christie PT, Grigorieva IV, Harding B, Van Esch H, Ahmed SF, et al. Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription actor. Hum Mol Genet 2007;16:265-275.
45. Barakat AY, D'Albora JB, Martin MM, Jose PA. Familial nephrosis, nerve deafness and hypoparathyroidism. J Pediatr 1977;91:61-64.
46. Shaw NJ, Haigh D, Lealmann GT, Karbani G, Brocklebank JT, Dillon MJ. Autosomal recessive hypoparathyroidism with renal insufficiency and developmental delay. Arch Dis Child 1991;66:1191-1194.
47. Richardson RJ, Kirk JM. Short stature, mental retardation and hypoparathyroidism: a new syndrome. Arch Dis Child 1990;65:1113-1117.
48. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990;322:1829-1836.
49. Arnold A, Horst SA, Gardella TJ, Baba H, Levine MA, Kronenberg HM. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest 1990;86:1084-1087.
50. Parkinson DB, Thakker RV. A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Nat Genet 1992;1:149-152.
51. Sunthornthepvarakul T, Churesigaew S, Ngowngarmratana S. A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J Clin Endocrinol Metab 1999;84:3792-3796.
52. Blomstrand S, Claesson I, Save-Soderbergh J. A case of lethal congenital dwarfism with accelerated skeletal maturation. Pediatr Radiol 1985;15:141-143.
53. Eiken M, Prag J, Petersen KE, Kaufmann HJ. A new familial skeletal dysplasia with severely retarded ossification and abnormal modeling of bones especially of the epiphyses, the hands and feet. Eur J Pediatr 1984;141:231-235.
54. Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 2001;22:675-705.
55. Hayward BE, Kamiya M, Strain L, Moran V, Campbell R, Hayashizaki Y, et al. The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci U S A 1998;95:10038-10043.
56. Nakamoto JM, Zimmerman D, Jones EA, Loke KY, Siddiq K, Donlan MA, et al. Concurrent hormone resistance (pseudohypoparathyroidism type Ia) and hormone independence (testotoxicosis) caused by a unique mutation in the G alpha s gene. Biochem Mol Med 1996;58:18-24.
57. Farfel Z. Pseudohypohyperparathyroidism-pseudohypoparathyroidism type Ib. J Bone Miner Res 1999;14:1016.
58. Zheng H, Radeva G, McCann JA, Hendy GN, Goodyer CG. Gαs transcripts are biallelically expressed in the human kidney cortex: implications for pseudohypoparathyroidism type 1b. J Clin Endocrinol Metab 2001;86:4627-4629.
59. Bastepe M, Jüppner H, Thakker RV. Parathroid disorders. In: Glorieux FH, Pettifor JM, Jüppner H, eds. Pediatric Bone: Biology & Diseases. San Diego: Academic Press, 2003, pp. 485-508.
60. Allgrove J, Adami S, Fraher L, Reuben A, O'Riordan JL. Hypomagnesaemia: studies of parathyroid hormone secretion and function. Clin Endocrinol (Oxf) 1984;21:435-449.
61. Khadilkar A, Das G, Sayyad M, Sanwalka N, Bhandari D, Khadilkar V, et al. Low calcium intake and hypovitaminosis D in adolescent girls. Arch Dis Child 2007;92:1045.
62. Thacher TD, Fischer PR, Strand MA, Pettifor JM. Nutritional rickets around the world: causes and future directions. Ann Trop Paediatr 2006;26:1-16.
63. Ladhani S, Srinivasan L, Buchanan C, Allgrove J. Presentation of vitamin D deficiency. Arch Dis Child 2004;89:781-784.
64. Mughal Z. Rickets in childhood. Semin Musculoskelet Radiol 2002;6:183-190.
65. Maiya S, Sullivan I, Allgrove J, Archer N, Tulloh R, Daubeney P, et al. Hypocalcaemia and Vitamin D deficiency: an but preventable cause of life threatening infant heart failure. Heart 2007;94:581-584.
66. Arnaud SB, Arnaud CD, Bordier PJ. The interrelationships between vitamin D and parathyroid hormone in disorders of mineral metabolism in man. In: Norman AW, ed. Vitamin D and Problems of Uremic Bone Disease. de Gruyter, 1975, pp. 397-416.
67. Papapoulos SE, Clemens TL, Fraher LJ, Gleed J, O'Riordan JL. Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol. Lancet 1980;2:612-615.
68. Casella SJ, Reiner BJ, Chen TC, Holick MF, Harrison HE. A possible genetic defect in 25-hydroxylation as a cause of rickets. J Pediatr 1994;124:929-932.
69. Fry AC, Karet FE. Inherited renal acidoses. Physiology (Bethesda) 2007;22:202-211.
70. Annemans L, Moeremans K, Lamotte M, Garcia CJ, van den BH, Myint H, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 2003;11:249-257.
71. Salusky IB, Goodman WG. Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Kidney Int 1995;48:657-665.
72. KDOQI NKF. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005;46: S1-121.
73. Lloyd SE, Pannett AA, Dixon PH, Whyte MP, Thakker RV. Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Am J Hum Genet 1999;64:189-195.
74. McMurtry CT, Schranck FW, Walkenhorst DA, Murphy WA, Kocher DB, Teitelbaum SL, et al. Significant developmental elevation in serum parathyroid hormone concentrations in a large kindred with familial benign (hypocalciuric) hypercalcemia. Am J Med 1992;93:247-258.
75. Pearce S, Steinmann B. Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism. Clin Endocrinol (Oxf) 1999;50:691-693.
76. Pannett AA, Thakker RV. Multiple endocrine neoplasia type 1. Endocr Relat Cancer 1999;6:449-473.
77. Thakker RV. Multiple endocrine neoplasia: syndromes of the twentieth century. J Clin Endocrinol Metab 1998;83:2617-2620.
78. Williamson C, Pannett AA, Pang JT, Wooding C, McCarthy M, Sheppard MN, et al. Localisation of a gene causing endocrine neoplasia to a 4 cM region on chromosome 1p35-p36. J Med Genet 1997;34:617-619.
79. Szabo J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 1995;56:944-950.
80. Weinstein LS, Simonds WF. HRPT2, a marker of parathyroid cancer. N Engl J Med 2003;349:1691-1692.
81. Cetani F, Pardi E, Bycava P, Pollina GD, Fanelli G, Picone A, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 2004;60:99-106.
82. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-515.
83. Odell WD, Hobbs MR, Benowitz B. An immunologically anomolous parathyroid hormone variant causing hyperparathyroidism. Clin Endocrinol (Oxf) 2001;55:417-420.
84. Schipani E, Langman C, Hunzelman J, Le Merrer M, Loke KY, Dillon MJ, et al. A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 1999;84:3052-3057.
85. Burden AD, Krafchik BR. Subcutaneous fat necrosis of the newborn: a review of 11 cases. Pediatr Dermatol 1999;16:384-387.
86. Chesney RW, Hamstra AJ, DeLuca HF, Horowitz S, Gilbert EF, Hong R, et al. Elevated serum 1,25-dihydroxyvitamin D concentrations in the hypercalcemia of sarcoidosis: correction by glucocorticoid therapy. J Pediatr 1981;98:919-922.
87. American Academy of Pediatrics. Health care supervision for children with Williams syndrome. Pediatrics 2001;107:1192- 1204.
88. Perez Jurado LA, Peoples R, Kaplan P, Hamel BC, Francke U. Molecular definition of the chromosome 7 deletion in Williams syndrome and parent-of-origin effects on growth. Am J Hum Genet 1996;59:781-792.
89. McTaggart SJ, Craig J, MacMillan J, Burke JR. Familial occurrence of idiopathic infantile hypercalcemia. Pediatr Nephrol 1999;13:668-671.
90. Kaul S, Sockalosky JJ. Human synthetic calcitonin therapy for hypercalcemia of immobilization. J Pediatr 1995;126:825-827.
91. McKay C, Furman WL. Hypercalcemia complicating childhood malignancies. Cancer 1993;72:256-260.
92. Cole DE. Hypophosphatasia update: recent advances in diagnosis and treatment. Clin Genet 2008;73:232-235.
93. Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev 1994;15:439-461.
94. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest 2005;115:3318-3325.
95. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101-116.
96. Zack P, Zack LR, Surtees R, Neville BG. A standardized tool to measure and describe scleral colour in osteogenesis imperfecta. Ophthalmic Physiol Opt 2007;27:174-178.
97. Goldman AB, Davidson D, Pavlov H, Bullough PG. Popcorn calcifications: a prognostic sign in osteogenesis imperfecta. Radiology 1980;136:351-358.
98. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000;15:1650-1658.
99. Cheung MS, Glorieux FH, Rauch F. Natural history of hyperplastic callus formation in osteogenesis imperfecta type V. J Bone Miner Res 2007;22:1181-1186.
100. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002;17:30-38.
101. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002;31:12-18.
102. Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007;39:359-365.
103. Rauch F, Travers R, Norman ME, Taylor A, Parfitt AM, Glorieux FH. Deficient bone formation in idiopathic juvenile osteoporosis: a histomorphometric study of cancellous iliac bone. J Bone Miner Res 2000;15:957-963.
104. Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol 1995;34:68-77.
105. Smith R. Idiopathic osteoporosis in the young. J Bone Joint Surg Br 1980;62-B: 417-427.
106. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM. Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005;353:918-923.
107. Rauch F, Glorieux FH. Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet C Semin Med Genet 2005;139:31-37.
108. Fischer A, Griscelli C, Friedrich W, Kubanek B, Levinsky R, Morgan G, et al. Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985. Lancet 1986;2:1080-1084.
109. Key L, Carnes D, Cole S, Holtrop M, Bar-Shavit Z, Shapiro F, et al. Treatment of congenital osteopetrosis with high-dose calcitriol. N Engl J Med 1984;310:409-415.
110. Key LL Jr, Rodriguiz RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 1995;332:1594-1599.
111. Janssens K, Van Hul W. Molecular genetics of too much bone. Hum Mol Genet 2002;11:2385-2393.
112. Ariceta G, Langman CB. Growth in X-linked hypophosphatemic rickets. Eur J Pediatr 2007;166:303-309.
113. Borghi MM, Coates V, Omar HA. Evaluation of stature development during childhood and adolescence in individuals with familial hypophosphatemic rickets. Sci World J 2005;5:868-873.
114. Quigley R. Proximal renal tubular acidosis. J Nephrol 2006;19 (Suppl 9): S41-45.
115. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003;88:4569-4575.
116. Bouthors J, Vantyghem MC, Manouvrier-Hanu S, Soudan B, Proust E, Happle R, et al. Phacomatosis pigmentokeratotica associated with hypophosphataemic rickets, pheochromocytoma and multiple basal cell carcinomas. Br J Dermatol 2006;155:225-226.
117. Hoffman WH, Jueppner HW, Deyoung BR, O'dorisio MS, Given KS. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet A 2005;134:233-236.
118. Saraswat A, Dogra S, Bansali A, Kumar B. Phakomatosis pigmentokeratotica associated with hypophosphataemic vitamin Dresistant rickets: improvement in phosphate homeostasis after partial laser ablation. Br J Dermatol 2003;148:1074-1076.
119. Shah BR, Finberg L. Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method. J Pediatr 1994;125:487-490.
120. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005;90:494-499.
121. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119 (Suppl 2): S150-S162.
122. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222s-6230s.
123. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952.
124. Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 2007;40:821-827.
125. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-463.
126. Festen-Spanjer B, Haring CM, Koster JB, Mudde AH. Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia. Clin Endocrinol (Oxf) 2008;68:324-325.
127. Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 2006;260:177-182.